Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168812 | PMC |
| http://dx.doi.org/10.1093/neuonc/noab048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DHODH Inhibition Suppresses and Inhibits the Growth of Medulloblastoma in a Novel In Vivo Zebrafish Model.
Cancers (Basel)
December 2024
Division of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden.
Background/objectives: Medulloblastoma (MB) is the most common high-grade paediatric brain tumour, with group 3 MB patients having the worst prognosis. A high prevalence of group 3 tumours shows overexpression of the oncogene, making it a potential therapeutic target. However, attempts to directly inhibit have so far demonstrated limited success.
View Article and Find Full Text PDFNanopore Sequencing as a Cutting-Edge Technology for Medulloblastoma Classification.
Neuro Oncol
December 2024
Genetics Department, Institut Curie, Paris, France.
Background: Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into four molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis.
View Article and Find Full Text PDFSingle-cell multi-omics analysis identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma.
Res Sq
December 2024
Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Medulloblastoma (MB) is the most prevalent malignant brain tumor in children, exhibiting clinical and genomic heterogeneity. Of the four major subgroups, Group 3 tumors (MYC-MB), display high levels of MYC and metastasis rates. Despite treatment with surgery, radiation, and chemotherapy, patients with Group 3 MB are more likely to develop aggressive recurrent tumors with poor survival.
View Article and Find Full Text PDFEpidemiology and clinical outcomes of childhood central nervous system cancers in a large low-middle income country pediatric oncology center: a report on 5051 kids.
Cancer Epidemiol Biomarkers Prev
December 2024
National Cancer Institute, Cairo, Egypt, Egypt.
Background: Central nervous system (CNS) tumors are the leading cause of cancer-related deaths in children. While most cases come from low-middle income countries (LMIC) where their prognosis is worse, few epidemiological studies are conducted in these regions.
Methods: We conducted a registry-based cohort study for childhood CNS tumors at Children's Cancer Hospital, Egypt (CCHE) over 15 years.
The impact of nutritional status on treatment-related toxicities in children with embryonal brain tumors: The need for proactive nutritional management.
Indian J Cancer
December 2024
Division of Pediatric Oncology, Tata Memorial Hospital, Mumbai, India.
Article Synopsis
- Children undergoing treatment for embryonal brain tumors face a high risk of malnutrition, with 64% undernourished at the start of chemotherapy and 61% remaining undernourished by the end.
- The study found that while undernourished children experienced higher rates of chemotherapy toxicity and infections, these findings were not statistically significant.
- Despite the nutritional challenges, the children’s nutritional status did not have a notable impact on overall survival rates, highlighting the need for ongoing nutritional monitoring and interventions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!